Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment.

Salahuddin S, Thomson E, Méziane O, Farnos O, Pagliuzza A, Chomont N, Olivenstein R, Costiniuk C, Jenabian MA.

J Vis Exp. 2019 Jun 23;(148). doi: 10.3791/59427.

PMID:
31282892
2.

HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy.

Miller RL, Ponte R, Jones BR, Kinloch NN, Omondi FH, Jenabian MA, Dupuy FP, Fromentin R, Brassard P, Mehraj V, Chomont N, Poon AFY, Joy JB, Brumme ZL, Routy JP; ORCHID Study Group.

J Virol. 2019 Aug 13;93(17). pii: e00755-19. doi: 10.1128/JVI.00755-19. Print 2019 Sep 1.

PMID:
31189714
3.

Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol.

Routy JP, Isnard S, Mehraj V, Ostrowski M, Chomont N, Ancuta P, Ponte R, Planas D, Dupuy FP, Angel JB; Lilac Study Group.

BMJ Open. 2019 Apr 20;9(4):e028444. doi: 10.1136/bmjopen-2018-028444.

4.

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group.

Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15.

PMID:
31000477
5.

Clinical correlates of HIV-1 DNA and inducible HIV-1 RNA reservoirs in peripheral blood in children with perinatally acquired HIV-1 infection with sustained virologic suppression for at least 5 years.

Bitnun A, Ransy DG, Brophy J, Kakkar F, Hawkes M, Samson L, Annabi B, Pagliuzza A, Morand JA, Sauve L, Chomont N, Lavoie S, Kim J, Sandstrom P, Wender P, Lee T, Singer J, Read SE, Soudeyns H; EPIC Research Group.

Clin Infect Dis. 2019 Mar 28. pii: ciz251. doi: 10.1093/cid/ciz251. [Epub ahead of print]

PMID:
30919879
6.

Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy.

Takata H, Kessing C, Sy A, Lima N, Sciumbata J, Mori L, Jones RB, Chomont N, Michael NL, Valente S, Trautmann L.

J Virol. 2019 May 15;93(11). pii: e02248-18. doi: 10.1128/JVI.02248-18. Print 2019 Jun 1.

PMID:
30918072
7.

Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection.

Pardons M, Baxter AE, Massanella M, Pagliuzza A, Fromentin R, Dufour C, Leyre L, Routy JP, Kaufmann DE, Chomont N.

PLoS Pathog. 2019 Feb 27;15(2):e1007619. doi: 10.1371/journal.ppat.1007619. eCollection 2019 Feb.

8.

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals.

Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, Hoh R, Deeks SG, Hazuda DJ, Lewin SR, Routy JP, Sékaly RP, Chomont N.

Nat Commun. 2019 Feb 18;10(1):814. doi: 10.1038/s41467-019-08798-7.

9.

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation.

Costiniuk CT, Saneei Z, Routy JP, Margolese S, Mandarino E, Singer J, Lebouché B, Cox J, Szabo J, Brouillette MJ, Klein MB, Chomont N, Jenabian MA.

BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793.

10.

Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4+ T Cells and Offers an Opportunity to Tackle Infection.

Valle-Casuso JC, Angin M, Volant S, Passaes C, Monceaux V, Mikhailova A, Bourdic K, Avettand-Fenoel V, Boufassa F, Sitbon M, Lambotte O, Thoulouze MI, Müller-Trutwin M, Chomont N, Sáez-Cirión A.

Cell Metab. 2019 Mar 5;29(3):611-626.e5. doi: 10.1016/j.cmet.2018.11.015. Epub 2018 Dec 20.

PMID:
30581119
11.

Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation.

Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A, Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M, Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG.

J Infect Dis. 2019 Mar 15;219(7):1084-1094. doi: 10.1093/infdis/jiy617.

PMID:
30371873
12.

Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals.

Uzzan M, Tokuyama M, Rosenstein AK, Tomescu C, SahBandar IN, Ko HM, Leyre L, Chokola A, Kaplan-Lewis E, Rodriguez G, Seki A, Corley MJ, Aberg J, La Porte A, Park EY, Ueno H, Oikonomou I, Doron I, Iliev ID, Chen BK, Lui J, Schacker TW, Furtado GC, Lira SA, Colombel JF, Horowitz A, Lim JK, Chomont N, Rahman AH, Montaner LJ, Ndhlovu LC, Mehandru S.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaau4711. doi: 10.1126/scitranslmed.aau4711.

13.

HIV persistence in mucosal CD4+ T cells within the lungs of adults receiving long-term suppressive antiretroviral therapy.

Costiniuk CT, Salahuddin S, Farnos O, Olivenstein R, Pagliuzza A, Orlova M, Schurr E, De Castro C, Bourbeau J, Routy JP, Ancuta P, Chomont N, Jenabian MA.

AIDS. 2018 Oct 23;32(16):2279-2289. doi: 10.1097/QAD.0000000000001962.

14.

Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir.

Das B, Dobrowolski C, Luttge B, Valadkhan S, Chomont N, Johnston R, Bacchetti P, Hoh R, Gandhi M, Deeks SG, Scully E, Karn J.

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7795-E7804. doi: 10.1073/pnas.1803468115. Epub 2018 Jul 30.

15.

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.

Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, Rolland M, Takata H, Buranapraditkun S, Intasan J, Chomchey N, Muir R, Haddad EK, Tovanabutra S, Ubolyam S, Bolton DL, Fullmer BA, Gorelick RJ, Fox L, Crowell TA, Trichavaroj R, O'Connell R, Chomont N, Kim JH, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV411 study group.

Nat Med. 2018 Jul;24(7):923-926. doi: 10.1038/s41591-018-0026-6. Epub 2018 Jun 11.

16.

Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size.

Teigler JE, Leyre L, Chomont N, Slike B, Jian N, Eller MA, Phanuphak N, Kroon E, Pinyakorn S, Eller LA, Robb ML, Ananworanich J, Michael NL, Streeck H, Krebs SJ; RV254/RV217 study groups.

JCI Insight. 2018 May 17;3(10). pii: 98420. doi: 10.1172/jci.insight.98420. eCollection 2018 May 17.

17.

Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency.

Evans VA, van der Sluis RM, Solomon A, Dantanarayana A, McNeil C, Garsia R, Palmer S, Fromentin R, Chomont N, Sékaly RP, Cameron PU, Lewin SR.

AIDS. 2018 Jul 17;32(11):1491-1497. doi: 10.1097/QAD.0000000000001849.

18.

Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA.

Psomas CK, Lafeuillade A, Margolis D, Salzwedel K, Stevenson M, Chomont N, Poli G, Routy JP.

J Virus Erad. 2018 Apr 1;4(2):132-142.

19.

Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise.

Plantin J, Massanella M, Chomont N.

Retrovirology. 2018 Jan 17;15(1):9. doi: 10.1186/s12977-017-0385-y. Review.

20.

Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments.

Crowell TA, Colby DJ, Pinyakorn S, Fletcher JLK, Kroon E, Schuetz A, Krebs SJ, Slike BM, Leyre L, Chomont N, Jagodzinski LL, Sereti I, Utay NS, Dewar R, Rerknimitr R, Chomchey N, Trichavaroj R, Valcour VG, Spudich S, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV254/SEARCH010 Study Group.

Clin Infect Dis. 2018 May 2;66(10):1540-1549. doi: 10.1093/cid/cix1063.

21.

Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.

Cummins NW, Rizza S, Litzow MR, Hua S, Lee GQ, Einkauf K, Chun TW, Rhame F, Baker JV, Busch MP, Chomont N, Dean PG, Fromentin R, Haase AT, Hampton D, Keating SM, Lada SM, Lee TH, Natesampillai S, Richman DD, Schacker TW, Wietgrefe S, Yu XG, Yao JD, Zeuli J, Lichterfeld M, Badley AD.

PLoS Med. 2017 Nov 28;14(11):e1002461. doi: 10.1371/journal.pmed.1002461. eCollection 2017 Nov.

22.

Wake me up before you go: a strategy to reduce the latent HIV reservoir.

Chomont N, Okoye AA, Favre D, Trautmann L.

AIDS. 2018 Jan 28;32(3):293-298. doi: 10.1097/QAD.0000000000001695. No abstract available.

23.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

24.

The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research.

Mehraj V, Ghali P, Ramendra R, Costiniuk C, Lebouché B, Ponte R, Reinhard R, Sousa J, Chomont N, Cohen EA, Ancuta P, Routy JP.

J Virus Erad. 2017 Oct 1;3(4):212-217.

25.

Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants.

Hiener B, Horsburgh BA, Eden JS, Barton K, Schlub TE, Lee E, von Stockenstrom S, Odevall L, Milush JM, Liegler T, Sinclair E, Hoh R, Boritz EA, Douek D, Fromentin R, Chomont N, Deeks SG, Hecht FM, Palmer S.

Cell Rep. 2017 Oct 17;21(3):813-822. doi: 10.1016/j.celrep.2017.09.081.

26.

Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique.

Baxter AE, Niessl J, Fromentin R, Richard J, Porichis F, Massanella M, Brassard N, Alsahafi N, Routy JP, Finzi A, Chomont N, Kaufmann DE.

Nat Protoc. 2017 Oct;12(10):2029-2049. doi: 10.1038/nprot.2017.079. Epub 2017 Sep 7.

27.

Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy.

Khoury G, Fromentin R, Solomon A, Hartogensis W, Killian M, Hoh R, Somsouk M, Hunt PW, Girling V, Sinclair E, Bacchetti P, Anderson JL, Hecht FM, Deeks SG, Cameron PU, Chomont N, Lewin SR.

J Infect Dis. 2017 Mar 15;215(6):911-919. doi: 10.1093/infdis/jix039.

28.

Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection.

Takata H, Buranapraditkun S, Kessing C, Fletcher JL, Muir R, Tardif V, Cartwright P, Vandergeeten C, Bakeman W, Nichols CN, Pinyakorn S, Hansasuta P, Kroon E, Chalermchai T, O'Connell R, Kim J, Phanuphak N, Robb ML, Michael NL, Chomont N, Haddad EK, Ananworanich J, Trautmann L; RV254/SEARCH010 and the RV304/SEARCH013 Study Groups.

Sci Transl Med. 2017 Feb 15;9(377). pii: eaag1809. doi: 10.1126/scitranslmed.aag1809.

29.

Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection.

Tawakol A, Ishai A, Li D, Takx RA, Hur S, Kaiser Y, Pampaloni M, Rupert A, Hsu D, Sereti I, Fromentin R, Chomont N, Ganz P, Deeks SG, Hsue PY.

JAMA Cardiol. 2017 Feb 1;2(2):163-171. doi: 10.1001/jamacardio.2016.4728.

30.

HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy.

Gosselin A, Wiche Salinas TR, Planas D, Wacleche VS, Zhang Y, Fromentin R, Chomont N, Cohen ÉA, Shacklett B, Mehraj V, Ghali MP, Routy JP, Ancuta P.

AIDS. 2017 Jan 2;31(1):35-48.

31.

Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.

Sereti I, Krebs SJ, Phanuphak N, Fletcher JL, Slike B, Pinyakorn S, O'Connell RJ, Rupert A, Chomont N, Valcour V, Kim JH, Robb ML, Michael NL, Douek DC, Ananworanich J, Utay NS; RV254/SEARCH 010, RV304/SEARCH 013 and SEARCH 011 protocol teams.

Clin Infect Dis. 2017 Jan 15;64(2):124-131. doi: 10.1093/cid/ciw683. Epub 2016 Oct 12.

32.

DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.

Thompson M, Heath SL, Sweeton B, Williams K, Cunningham P, Keele BF, Sen S, Palmer BE, Chomont N, Xu Y, Basu R, Hellerstein MS, Kwa S, Robinson HL.

PLoS One. 2016 Oct 6;11(10):e0163164. doi: 10.1371/journal.pone.0163164. eCollection 2016.

33.

Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults.

Jenabian MA, Costiniuk CT, Mehraj V, Ghazawi FM, Fromentin R, Brousseau J, Brassard P, Bélanger M, Ancuta P, Bendayan R, Chomont N, Routy JP; Orchid study group.

AIDS. 2016 Nov 28;30(18):2777-2786.

PMID:
27677162
34.

Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation.

Crowell TA, Fletcher JL, Sereti I, Pinyakorn S, Dewar R, Krebs SJ, Chomchey N, Rerknimitr R, Schuetz A, Michael NL, Phanuphak N, Chomont N, Ananworanich J; RV254/SEARCH010 Study Group.

J Int AIDS Soc. 2016 Sep 15;19(1):21163. doi: 10.7448/IAS.19.1.21163. eCollection 2016.

35.

New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy.

Wacleche VS, Goulet JP, Gosselin A, Monteiro P, Soudeyns H, Fromentin R, Jenabian MA, Vartanian S, Deeks SG, Chomont N, Routy JP, Ancuta P.

Retrovirology. 2016 Aug 24;13(1):59. doi: 10.1186/s12977-016-0293-6.

36.

Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals.

Baxter AE, Niessl J, Fromentin R, Richard J, Porichis F, Charlebois R, Massanella M, Brassard N, Alsahafi N, Delgado GG, Routy JP, Walker BD, Finzi A, Chomont N, Kaufmann DE.

Cell Host Microbe. 2016 Sep 14;20(3):368-380. doi: 10.1016/j.chom.2016.07.015. Epub 2016 Aug 18.

37.

Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy.

Lee SA, Bacchetti P, Chomont N, Fromentin R, Lewin SR, O'Doherty U, Palmer S, Richman DD, Siliciano JD, Yukl SA, Deeks SG, Burbelo PD.

PLoS One. 2016 Aug 2;11(8):e0160192. doi: 10.1371/journal.pone.0160192. eCollection 2016.

38.

Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA.

Margolis DM, Salzwedel K, Chomont N, Psomas C, Routy JP, Poli G, Lafeuillade A.

J Virus Erad. 2016 Jan 1;2(1):57-65.

39.

HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART.

Ananworanich J, Chomont N, Eller LA, Kroon E, Tovanabutra S, Bose M, Nau M, Fletcher JLK, Tipsuk S, Vandergeeten C, O'Connell RJ, Pinyakorn S, Michael N, Phanuphak N, Robb ML; RV217 and RV254/SEARCH010 study groups.

EBioMedicine. 2016 Sep;11:68-72. doi: 10.1016/j.ebiom.2016.07.024. Epub 2016 Jul 20.

40.

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART.

Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, Killian M, Epling L, Hoh R, Sinclair E, Hecht FM, Bacchetti P, Deeks SG, Lewin SR, Sékaly RP, Chomont N.

PLoS Pathog. 2016 Jul 14;12(7):e1005761. doi: 10.1371/journal.ppat.1005761. eCollection 2016 Jul.

41.

International AIDS Society global scientific strategy: towards an HIV cure 2016.

Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F; International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J.

Nat Med. 2016 Aug;22(8):839-50. doi: 10.1038/nm.4108. Epub 2016 Jul 11.

42.

Strategies for targeting residual HIV infection.

Chomont N, Perreau M.

Curr Opin HIV AIDS. 2016 Jul;11(4):359-61. doi: 10.1097/COH.0000000000000291. No abstract available.

43.

Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site.

Huang Y, Hoque MT, Jenabian MA, Vyboh K, Whyte SK, Sheehan NL, Brassard P, Bélanger M, Chomont N, Fletcher CV, Routy JP, Bendayan R.

J Antimicrob Chemother. 2016 Jul;71(7):1954-65. doi: 10.1093/jac/dkw046. Epub 2016 Apr 13.

44.

Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy.

Tincati C, Merlini E, Braidotti P, Ancona G, Savi F, Tosi D, Borghi E, Callegari ML, Mangiavillano B, Barassi A, Bulfamante G, d'Arminio Monforte A, Romagnoli S, Chomont N, Marchetti G.

AIDS. 2016 Apr 24;30(7):991-1003. doi: 10.1097/QAD.0000000000001015.

PMID:
27028142
45.

Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection.

Ananworanich J, Sacdalan CP, Pinyakorn S, Chomont N, de Souza M, Luekasemsuk T, Schuetz A, Krebs SJ, Dewar R, Jagodzinski L, Ubolyam S, Trichavaroj R, Tovanabutra S, Spudich S, Valcour V, Sereti I, Michael N, Robb M, Phanuphak P, Kim JH, Phanuphak N.

J Virus Erad. 2016;2:43-48.

46.

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.

Ananworanich J, Chomont N, Fletcher JL, Pinyakorn S, Schuetz A, Sereti I, Rerknimitr R, Dewar R, Kroon E, Vandergeeten C, Trichavaroj R, Chomchey N, Chalermchai T, Michael NL, Kim JH, Phanuphak P, Phanuphak N.

J Virus Erad. 2015;1(2):116-122. Epub 2015 Apr 1.

47.

Loss of Function of Intestinal IL-17 and IL-22 Producing Cells Contributes to Inflammation and Viral Persistence in SIV-Infected Rhesus Macaques.

Ryan ES, Micci L, Fromentin R, Paganini S, McGary CS, Easley K, Chomont N, Paiardini M.

PLoS Pathog. 2016 Feb 1;12(2):e1005412. doi: 10.1371/journal.ppat.1005412. eCollection 2016 Feb.

48.

Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy.

Khoury G, Anderson JL, Fromentin R, Hartogenesis W, Smith MZ, Bacchetti P, Hecht FM, Chomont N, Cameron PU, Deeks SG, Lewin SR.

AIDS. 2016 Jun 19;30(10):1511-20. doi: 10.1097/QAD.0000000000001029.

49.

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.

Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, Gordon I, Casazza J, Conan-Cibotti M, Migueles SA, Tressler R, Bailer RT, McDermott A, Narpala S, O'Dell S, Wolf G, Lifson JD, Freemire BA, Gorelick RJ, Pandey JP, Mohan S, Chomont N, Fromentin R, Chun TW, Fauci AS, Schwartz RM, Koup RA, Douek DC, Hu Z, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE; VRC 601 Study Team.

Sci Transl Med. 2015 Dec 23;7(319):319ra206. doi: 10.1126/scitranslmed.aad5752.

PMID:
26702094
50.

Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach.

Cleret-Buhot A, Zhang Y, Planas D, Goulet JP, Monteiro P, Gosselin A, Wacleche VS, Tremblay CL, Jenabian MA, Routy JP, El-Far M, Chomont N, Haddad EK, Sekaly RP, Ancuta P.

Retrovirology. 2015 Dec 10;12:102. doi: 10.1186/s12977-015-0226-9.

Supplemental Content

Loading ...
Support Center